Navigation Links
DX-88 for Hereditary Angioedema Meets Primary and Secondary,Endpoints in Phase 3 Trial (EDEMA3)

60760258

A replay of the webcast will be available through May 17, 2007 and may be accessed by dialing 1-888-286-8010. International callers should dial 617-801-6888. The replay passcode for all callers is 25344900. The webcast will be archived on the Dyax website for an indefinite period of time.

About Dyax

Dyax is focused on advancing novel biotherapeutics for unmet medical needs, with an emphasis on oncology and inflammatory indications. Dyax utilizes its proprietary drug discovery technology to identify antibody, small protein and peptide compounds for clinical development.

Dyax's lead product candidate is DX-88, a recombinant small protein that is currently in clinical trials for its therapeutic potential in two separate indications. Dyax has successfully completed three Phase 2 trials and a Phase 3 trial of DX-88 for the treatment of hereditary angioedema (HAE). A confirmatory study, known as EDEMA4, is planned and expected to begin in the first quarter of 2007. DX-88 has orphan drug designation in the U.S. and E.U., as well as Fast Track designation in the U.S. for the treatment of acute attacks of HAE.

Additionally, Dyax has successfully completed a Phase 1/2 trial of DX-88 for the prevention of blood loss during on-pump coronary artery bypass graft (CABG) procedures. Dyax is initiating a Phase 2 trial for further development of DX-88 in on-pump cardiothoracic surgery (CTS), including CABG and heart valve replacement or repair procedures.

Dyax identified DX-88 and other compounds in its pipeline using its patented phage display technology, which rapidly selects compounds that bind with high affinity and specificity to therapeutic targets. Dyax leverages this technology broadly with over 70 revenue-generating licenses and collaborations for therapeutic discovery, as well as in non-core areas such as affinity separations, diagnostic imaging, and research reagents.

Dyax is headquartered in Cambridge, Massachusett
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of C1-Esterase Inhibitor for Hereditary Angioedema
2. Lev Pharmaceuticals Reports Positive Results in Pivotal Phase III Trial for Hereditary Angioedema
3. ENDEAVOR IV Clinical Trial Meets Primary Endpoint
4. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
5. Second Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
6. Neoprobe Phase 2 Lymphoseek Trial Meets Primary Endpoint
7. Phase III Study Evaluating Gileads Viread for the Treatment of Chronic Hepatitis B Virus Meets Primary Endpoint
8. SciClone and Sigma-Tau Report Thymalfasin Meets Primary Endpoint in Phase 2 Malignant Melanoma Trial
9. GlaxoSmithKline’s Hib-MenCY-TT Combination Vaccine Meets Phase II Study Endpoints of Immunogenicity and Safety Compared to Licensed Vaccines
10. YM BioSciences Reports AeroLEF Randomized Phase IIb Trial Meets Primary Endpoint in Patients with Post-Surgical Pain
11. Alexzas AZ-004 Phase IIa Trial Meets Primary Endpoint in Treating Schizophrenic Patients With Acute Agitation
Post Your Comments:
(Date:7/24/2014)... , July 24, 2014  IRIDEX Corporation (NASDAQ: ... release its second quarter 2014 financial results after the ... In conjunction with the release, the Company will host ... 5:00 p.m. Eastern Time on Thursday, July ... quarter and other business developments. Interested parties ...
(Date:7/24/2014)... , July 24, 2014 Omnicell, Inc. ... of medication and supply management solutions and analytics ... Thursday, July 31, to discuss the Company,s Second ... Second Quarter 2014 earnings conference call and webcastWhen: ... , Randall Lipps, chairman, president and chief executive ...
(Date:7/24/2014)... 2014  IGI Laboratories, Inc. (NYSE MKT: IG), a New ... its financial results for the second quarter ended June 30, ... Total revenues of $6.5 million in the second quarter of ... 2013 , Total revenues of $13.3 million for the ... over the same period in 2013 , Total revenues ...
Breaking Medicine Technology:Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7
... OXIS International, Inc. (OTC Bulletin Board: OXIS ... named former Wal-Mart executive Ken Eaton to its Board ... including three independent Directors. "I am very ... the OXIS International Board of Directors," said Anthony J. ...
... June 27, 2011 Pacira Pharmaceuticals, Inc ., ... company, today announced that it has been included in ... its comprehensive set of U.S. and global equity indexes ... 3000 Index measures the performance of the 3,000 largest ...
Cached Medicine Technology:OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 2OXIS International Names Former Wal-Mart Executive Ken Eaton to Board of Directors 3Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 2Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index 3
(Date:7/25/2014)... Yisrayl Hawkins, Pastor and Overseer of The ... the pot by revealing to the whole world, including even ... Satan, the devil, in his new article. , Yisrayl says ... and carried out by the Catholic Church. He says this ... Inspired Holy Scriptures and replacing it with titles such as ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 Recently, the largest ... all its members and found that there had been a ... HSV and/or HPV virus. , Living with a sexually transmitted ... as there are many people from all around the world ... been diagnosed with one of many STDs including HSV, HPV, ...
(Date:7/25/2014)... As the category creator and world leader in healthy ... transform and improve individual lives worldwide through its exclusive and ... a successful Austin, Texas based "Xocai Activ Drink" author, is ... July to promote the up and coming mxicorp.com/company/igc Eric Worre ... has been a leader in the Network Marketing Profession for ...
(Date:7/24/2014)... Lawrence, KS (PRWEB) July 25, 2014 ... implant can be affected by the width of the ... to hold the implant. A variety of methods exist, ... and subsequent augmentation techniques. The ridge-split graft is highlighted ... , The Journal of Oral Implantology offers a ...
(Date:7/24/2014)... A few weeks have passed since ... high jump by Inika McPherson is a feat to ... USATF National Championships hosted the best track and field ... won US Nationals with the 2nd best jump in ... the biggest height over head jump in history. , ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Says You Have Been Tricked Into Worshipping Satan in New Article 2Health News:The Number of People Living With HSV and HPV Greatly Increased- Survey on PositiveSingles.com 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 2Health News:A Comparison of Graft Techniques for the Alveolar Ridge Prior to Oral Implant 3Health News:Setting A New High Jump World Record In Zensah® Compression 2Health News:Setting A New High Jump World Record In Zensah® Compression 3
... ... the United States will be working in the fields. Although the United States was one ... continues to allow children to work long hours in hazardous jobs. , ... Washington, D.C.(Vocus) June 11, 2010 -- Today on ...
... ... distribution operations for the company’s new product line, the CR Series Load & Go™ ... ... of a new manufacturing facility in Miramar, Florida. The new facility will support ...
... ... Advanced Imaging Consultants have finalized their partnership, that will make UltraLinq,s exam reporting ... and operations solution for mobile and outreach imaging businesses. , ... New York, NY (PRWEB) ...
... blood supply, but urge more research , SATURDAY, June 12 (HealthDay ... panel of experts on Friday voted to uphold a decades-old ban ... the controversial issue. , The current policy -- put into effect ... prevents any man who since 1977 has had sex with another ...
... will be ineffective , SATURDAY, June 12 (HealthDay ... to treatment for hepatitis C infection has been identified ... 1,362 hepatitis C patients and pinpointed the variant in ... occurs in a gene called IL28B, which encodes for ...
... Leading Gulf Coast medical centers, universities and public health ... a consortium to improve community disaster readiness and recovery ... environmental health. The consortium, known as SECURE ... funded through a two-year, $4 million grant from the ...
Cached Medicine News:Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 2Health News:AFOP's Children in the Fields Campaign Raises Awareness of Child Labor in the U.S. 3Health News:UltraLinq Healthcare Solutions and Advanced Imaging Consultants Partner to Provide an Anytime, Anywhere Image Management Solution to the Mobile Market 2Health News:UltraLinq Healthcare Solutions and Advanced Imaging Consultants Partner to Provide an Anytime, Anywhere Image Management Solution to the Mobile Market 3Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 2Health News:U.S. Panel Upholds Ban on Gay Men as Blood Donors 3Health News:Research alliance aims to help vulnerable communities cope with disaster 2Health News:Research alliance aims to help vulnerable communities cope with disaster 3Health News:Research alliance aims to help vulnerable communities cope with disaster 4
... is the premium CPAP device in ResMeds new ... line of flow generators are the smallest on ... to include an option of fully integrated heated ... for simplicity and convenience. Premium S8 models also ...
... freedom and flexibility with the integrated ... battery pack, the system will be ... Also includes an integrated heated humidifier. ... water for one nights use, and ...
... is the smallest and lightest continuous positive ... It is designed to help active sleep ... with therapy. The GoodKnight 420S model records ... data. It also detects persistent residual apnea, ...
The clarity and performance of glass with shatterproof safety of plastic....
Medicine Products: